U.S. stocks closed mildly higher Monday in low volume trade as investors readied for the first major earnings reports due Tuesday.» Read More
Sept 8- Tetraphase Pharmaceuticals Inc said its experimental bowel drug failed to meet the main goal in a late-stage study, sending its shares down 75 percent in extended trading. The company said on Tuesday that data from the study showed that the drug was not better than Johnson& Johnson's antibiotic, levofloxacin, to treat complicated urinary tract...
U.S. stocks closed more than 1 percent lower ahead of a long weekend as uncertainty about the timing of a rate hike and Chinese growth weighed.
Sept 2- The U.S. Food and Drug Administration approved Tesaro Inc's treatment for chemotherapy-induced nausea and vomiting in adults, the company said on Wednesday. The drug, known chemically as rolapitant, was approved in combination with other agents to prevent delayed nausea and vomiting associated with some forms of chemotherapy, Tesaro said.
The FDA said it had identified 33 cases of severe joint pain in patients taking a class of drugs known as DPP-4 inhibitors between Oct. 16, 2006, when the first one was approved, through Dec. 31, 2013. Five cases were reported with AstraZeneca Plc's Onglyza, two with Boehringer Ingelheim's Tradjenta, and one with Takeda Pharmaceutical's Nesina.
U.S. stocks shot higher on Wednesday, rebounding from six consecutive days of declines that pushed the major averages into correction territory.
U.S. stocks closed lower, after a failed attempt to rally, as investor confidence waned amid continued concerns about China and global growth.
U.S. stocks closed near session lows as investors weighed continued uncertainty about the timing of a rate hike and concerns about global growth.
Stocks pared gains and closed mostly lower on Thursday.
Alex Arfaei of BMO Capital Markets upgraded Merck to "outperform" Thursday morning in a note sent to clients.
Some of the names on the move ahead of the open.
U.S. stocks closed off lows, recovering from sharp intraday declines as gains in energy offset earlier pressures from global growth concerns.
Pfizer Inc, which is lagging rivals in the lucrative field of cancer immunotherapies, has been the first to report early data of an "accelerator" treatment that targets a protein called 4-1 BB. Bristol-Myers Squibb Co is hot on Pfizer's heels with a handful of early-stage trials of its own 4-1 BB antibody. Holbrook Kohrt, a researcher from Stanford University...
Aug 6- Irish drugmaker Allergan Plc reported better-than-expected revenue for the first full quarter since the merger of Actavis and Allergan. Allergan, which changed its name from Actavis after the deal closed, said adding signature drugs like Botox and eye drops Restasis boosted branded products sales five-fold to $3.71 billion in the second quarter...
A vaccine being developed by Merck and NewLink was shown to be 100 percent effective, but does this mean they'll make big bucks?
An Ebola vaccine developed in record time has proved highly effective against the deadly virus in a large trial in Guinea.
BOSTON, July 30- Venezuela's currency woes cut nearly $3 billion in profit at U.S. blue-chip companies during the second quarter and prompted Procter& Gamble Co to remove its operations in the South American country from its consolidated financial reports. More so-called deconsolidation moves and exits from Venezuela are likely to happen during the second...
July 29- Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent, newly approved cholesterol drugs could "wreak financial havoc" among its clients. Express Scripts, which administers drug benefits for employers and health plans and also runs large mail-order pharmacies, has been challenging...
July 29- Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent new cholesterol drugs called PCSK9 inhibitors could "wreak financial havoc" among its clients. U.S. regulators on Friday approved the first of the new medicines, Praluent from Regeneron Pharmaceuticals Inc and Sanofi SA.
Raghuram Selvaraju, managing director for equity research healthcare division at MLV & Co, discusses the quarterly results of pharmaceutical giants such as Pfizer and Merck & Co.
CNBC's Meg Tirrell talks with Merck CEO Ken Frazier about the company's lung cancer drug Keytruda, and other drugs in the pipeline. Also Frazier weighs in on M&A in the pharma space and pricing pressures.